/ Not yet recruiting临床2期IIT Prospective Study to Assess the Efficacy of Letermovir Prophylaxis in Preventing CMV Infection in Lung Transplant Recipients Compared to a Retrospective Cohort Treated With Standard Valganciclovir Prophylaxis for 12 Months (LETERCOR Study)
The goal of this quasi-experimental multicenter before-after cohort study, phase II study is to evaluate the efficacy of 12-month letermovir prophylaxis in lung transplant recipients (D+/R-) compared to a historical cohort of lung transplant recipients (D+/R-) who received 12 months of valganciclovir prophylaxis to prevent CMV disease."
100 项与 Merck Sharp & Dohme de España SAU 相关的临床结果
0 项与 Merck Sharp & Dohme de España SAU 相关的专利（医药）
100 项与 Merck Sharp & Dohme de España SAU 相关的药物交易
100 项与 Merck Sharp & Dohme de España SAU 相关的转化医学
